Hamlins advise on the sale of InferMed Limited

Hamlins is delighted to announce that it has advised the founding shareholders of InferMed Limited on the successful sale of the entire share capital of the company to RELX (formerly Reed Elsevier) for an undisclosed sum.
InferMed Limited is a London-based clinical decision support (CDS) technology company, which previously won the prestigious Queen’s Award for Enterprise in Innovation 2012 in the UK for its work in developing and commercialising these decision support systems.

Launched in 1999 as a joint venture with the UK’s largest cancer charity, CRUK, InferMed has become a leader in providing software and services to the healthcare, pharmaceutical, and clinical research sectors with whom it works in close collaboration. InferMed’s products are now an integral part of the NHS’s operations and help healthcare providers to practise more efficiently.

The Hamlins team was led by corporate head Daniel Bellau with support from corporate associates Alice Kingdon and Charlotte Allan, media and IP partner Matthew Pryke and IP associate Sophie Arrowsmith.

Daniel Bellau explained;

“This was a particularly exciting transaction for us. Our team specialises in advising successful entrepreneurs in growing their businesses and achieving successful exits. We worked closely with the founders of InferMed in preparing their business for sale calling on Hamlins’ strength in the IP sector. We are therefore delighted to have assisted them to achieve a successful exit.”

Alan Montgomery, the founder and majority shareholder of InferMed stated;
“Working with Hamlins was a pleasure. They handled the complexities of the transaction superbly well whilst being a wonderfully friendly and responsive team to deal with during such a highly pressured time.”